Proposed Retail Offer

Manchester, UK - 23 September 2025: genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces a retail offer via BookBuild (the "Retail Offer") of new ordinary shares of 0.015 pence each ("Ordinary Shares") in the capital of the Company (the "Retail Offer Shares") at an issue price of 0.20 pence per new Ordinary Share (as defined below) (the "Issue Price").

In addition to the Retail Offer, the Company is also conducting a placing of new ordinary shares (the "Placing Shares" and together with the Retail Offer Shares, the "New Ordinary Shares") at the Issue Price (the "Placing" and together with the Retail Offer, the "Issue" or the "Fundraising").

A separate announcement has been made today with details of the Placing and its terms and conditions as well as setting out the background to the Fundraising and the use of proceeds (the "Launch Announcement"). The net proceeds of the Retail Offer will be utilised in the same way as the proceeds of the Placing. For the avoidance of doubt, the Retail Offer is not part of the Placing.

The Retail Offer is not part of the Placing. Completion of the Placing is not conditional on the completion of the Retail Offer. However, completion of the Retail Offer is conditional upon, inter alia,

the New Ordinary Shares to be issued pursuant to the Retail Offer being admitted to trading on the AIM market operated by the London Stock Exchange plc ("Admission"). Admission of the New Ordinary Shares pursuant to the Retail Offer is expected to take place on 16 October 2025. Completion of the Retail Offer is conditional, inter alia, upon the completion of the Placing.

The Placing Shares and the Retail Offer Shares will rank pari passu with the existing Ordinary Shares in issue.

Issue of Warrants

The Company has also agreed that subscribers in the Fundraising will receive one warrant for every one Ordinary Share subscribed for pursuant to the Fundraising, with each warrant entitling the holder to acquire one new Ordinary Share at a price of 0.40 pence at any time up to the second anniversary of the date of the Warrant Instrument, at which time they will lapse (the "Warrants"). Please see the Launch Announcement for more information on the Warrants.

Expected Timetable in relation to the Retail Offer

Retail Offer

The Company values its retail shareholder base. Given the support of retail shareholders, the Company believes that it is appropriate to provide its retail shareholders in the United Kingdom the opportunity to participate in the Retail Offer. The Company is therefore making the Retail Offer available in the United Kingdom through the financial intermediaries which will be listed, subject to certain access restrictions, on the following website: https://www.bookbuild.live/deals/V7XYM1/authorised-intermediaries

Allenby Capital Limited ("Allenby Capital") will be acting as retail offer coordinator in relation to this Retail Offer (the "Retail Offer Coordinator").

The Retail Offer will be open to eligible investors in the United Kingdom at 4:40pm on 23 September 2025. The Retail Offer is expected to close at 4:35pm on 26 September 2025. Investors should note that financial intermediaries may have earlier closing times. The Retail Offer may close early if it is oversubscribed.

There is a minimum subscription of £100 per investor under the terms of the Retail Offer which is open to eligible shareholders in the United Kingdom subscribing via the intermediaries which will be listed, subject to certain access restrictions, on the following website: https://www.bookbuild.live/deals/V7XYM1/authorised-intermediaries

Allenby Capital Limited - Joint Broker and Joint Bookrunner Nick Athanas / Vivek Bhardwaj (Corporate Finance) Amrit Nahal / Kelly Gardiner (Sales & Corporate Broking)

About genedrive plc (http://www.genedriveplc.com)

UK Product Governance Requirements

EU Product Governance Requirements

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Retail Offer Shares have been subject to a product approval process, which has determined that the Retail Offer Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "EU Target Market Assessment").

Notwithstanding the EU Target Market Assessment, distributors should note that: the price of the Retail Offer Shares may decline and investors could lose all or part of their investment; the Retail Offer Shares offer no guaranteed income and no capital protection; and an investment in the Retail Offer Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The EU Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Retail Offer.